

Cancer Treatments in the Top 5 European Countries

Paris, February 10, 2015 – [Cegedim Strategic Data](#) (CSD), a leading provider of healthcare market research, has released result highlights from its **OncoView®** study focusing on cancer treatments (excluding hormone therapy) in **France, Italy, Germany, Spain and UK**.

The study uses CSD's OncoView® databases for France, Italy, Germany, Spain and UK. CSD collects **anonymised** patient data through electronic case report forms (e-CRF) from a quarterly panel of 1 400 specialists. This analysis is based on 110,000 patient cases (raw data) and covers 12-month projected data on MAT¹ Q3 2014.

Result highlights

Bladder cancer ranks in the top four treated tumours for all five countries. It ranks second in Italy (15%) and Spain (13.2%); this is influenced by a wide use of intravesical therapies with chemotherapy by urologists in Italy and a wide use of pre- and post-surgery treatment by urologists for both Italy and Spain. Overall, bladder cancer represents 10% of all cancer treatments in the Top 5 European countries.

Treated Patients by Tumour Type
(excluding hormone therapy)

	FRANCE	GERMANY	ITALY	SPAIN	UK
Total Tumours	100%	100%	100%	100%	100%
Breast	16.9%	16.8%	15.3%	16.4%	14.7%
Non Small Cell Lung Cancer (NSCLC)	15.0%	12.3%	12.3%	11.0%	7.1%
Colorectal	9.8%	11.3%	10.5%	11.6%	10.7%
Bladder	6.3%	7.5%	15.0%	13.2%	10.4%
Non Hodgkin Lymphoma Aggressive	4.1%	4.7%	4.7%	3.7%	5.8%
Prostate	3.7%	3.2%	2.5%	2.7%	7.5%
Head & Neck	5.4%	3.0%	2.7%	5.7%	3.0%
Multiple Myeloma	3.3%	3.0%	3.5%	2.3%	3.1%
Ovary	2.7%	2.9%	2.6%	2.8%	3.4%
Pancreas	2.7%	3.0%	2.6%	2.5%	2.2%
Top 10 Tumours	69.8%	67.8%	71.6%	71.9%	67.9%


Source: Cegedim Strategic Data, OncoView®TOP5 EU

Notably, the top 10 cancers in the above table represent close to 70% of all cancer treated patients (excluding hormone therapy) in the Top 5 European countries.

Target Therapies

Between 500,000 and 600,000 patients are treated with target therapies in the Top 5 European countries. In the five countries studied target therapies represent an average of 32% of all cancer drugs used.

Use of Target Therapies by Country
(excluding hormone therapy)



Source: Cegedim Strategic Data, OncoView®TOP5 EU

Germany shows the highest rate of target therapy use (36%) compared to the other countries. The table below indicates the differences between the countries in terms of use of target therapies, by tumour type. These differences are influenced by the launch dates of the drugs and the health authority policies in each country.

Use of Target Therapies by Tumour & Country
(excluding hormone therapy)

	FRANCE	GERMANY	ITALY	SPAIN	UK
Breast	39.4%	41.4%	36.9%	31.3%	34.6%
Colorectal	38.7%	43.2%	31.4%	25.2%	30.6%
Non Small Cell Lung Cancer (NSCLC)	24.2%	27.0%	27.8%	32.2%	34.2%
Kidney	98.3%	99.8%	95.6%	97.9%	97.8%
Melanoma	61.0%	83.3%	61.6%	30.6%	84.8%
Liver	60.6%	62.4%	74.4%	77.6%	47.8%
Gastrointestinal Stromal Tumour (GIST)	100%	100%	99.3%	99.0%	100%
Non Hodgkin Lymphoma Aggressive	82.9%	85.1%	77.5%	78.1%	77.2%
Non Hodgkin Lymphoma Indolent	93.5%	96.1%	90.1%	92.0%	90.9%
Multiple Myeloma	63.6%	51.8%	62.9%	69.1%	33.0%
Chronic Myeloid Leukaemia	99.3%	98.1%	97.6%	97.7%	97.3%
Chronic Lymphocytic Leukaemia	84.6%	78.1%	65.8%	68.5%	69.7%

Source: Cegedim Strategic Data, OncoView®TOP5 EU

About Cegedim Strategic Data:

Cegedim Strategic Data (CSD) is a leading market research company dedicated to the healthcare industry and operating worldwide. With over 40 years' experience in the pharmaceutical industry, Cegedim Strategic Data offers a comprehensive range of market research services and solutions to its customers, which include more than 50 global and 500 local pharmaceutical companies. CSD integrates primary and secondary analyses with its medical expertise to meet its customer's research needs. To learn more, please visit our website: www.cegedimstrategicdata.com and follow Cegedim Strategic Data on Twitter [@CSDCegedim](https://twitter.com/CSDCegedim).

About Cegedim:

Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs almost 8,000 people in more than 80 countries and generated revenue of €912 million in 2014. Cegedim SA is listed in Paris (EURONEXT: CGM).

To learn more, please visit: www.cegedim.com and follow Cegedim on Twitter: [@CegedimGroup](https://twitter.com/CegedimGroup).

Contacts:

Pauline FAHEY
Cegedim Strategic Data
Marketing and Communications
Tel.: +33 (0)1 49 09 83 87
pauline.fahey@cegedim.com

Aude BALLEYDIER
Cegedim
Media Relations
Tel.: +33 (0)1 49 09 68 81
aude.balleydier@cegedim.com

Guillaume DE CHAMISSO
PRPA Agency
Press Officer
Tel.: +33 (0)1 77 35 60 99
guillaume.dechamisso@prpa.fr
